$116.28 $0.58 (0.5%)

03:38 PM EDT on 06/19/19

EXACT Sciences Corp (NASDAQ:EXAS)

CAPS Rating: 3 out of 5

An applied genomics company that develops proprietary DNA-based technologies for use in the detection of cancer.

Current Price $116.28 Mkt Cap $12.0B
Open $116.22 P/E Ratio 0.00
Prev. Close $115.70 Div. (Yield) $0.00 (0.0%)
Daily Range $115.40 - $117.61 Volume 191,822
52-Wk Range $61.00 - $117.61 Avg. Daily Vol.

Caps

How do you think NASDAQ:EXAS will perform against the market?

Add Stock to CAPS Watchlist

All Players

259 Outperform
37 Underperform
 

All-Star Players

60 Outperform
13 Underperform
 

Wall Street

12 Outperform
1 Underperform
 

Top NASDAQ:EXAS Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

ELPastor (< 20)
Submitted October 27, 2014

Most people, it is safe to say, do not enjoy getting a colonoscopy. Therefore, any company that offers a non-invasive colorectal cancer screening test has a good chance of squeezing out a nice, large profit.

zzlangerhans (99.78)
Submitted June 26, 2016

Exact stock does well when something happens to fuel speculation about the long-term profitability of Cologuard, and badly when actual quarterly revenues and losses are released. That reminds me of another stock that has a large cult following and… More

NASDAQ:EXAS VS S&P 500 (SPY)

Fools bullish on NASDAQ:EXAS are also bullish on:

Fools bearish on NASDAQ:EXAS are also bearish on:

Recent Community Commentary

Read the most recent pitches from players about EXAS.

Recs

0
Member Avatar Jack99 (76.80) Submitted: 5/14/2019 10:51:20 PM : Outperform Start Price: $91.37 NASDAQ:EXAS Score: +23.14

It has a huge addressable market

Recs

0
Member Avatar TMFang4apples (57.19) Submitted: 1/14/2019 5:44:23 PM : Outperform Start Price: $73.99 NASDAQ:EXAS Score: +43.44

It took a while, but I'm convinced.

Recs

0
Member Avatar jclaypool (73.00) Submitted: 7/22/2018 2:21:34 PM : Outperform Start Price: $67.67 NASDAQ:EXAS Score: +66.92

EXAS has a strong alternative product to a colonoscopy called Cologuard. With a proactive approach to getting patients to use the test kit EXAS is getting a higher compliance rate of users, which in turn makes the test more effective for physicians and insurers alike. While Cologuard is the growing revenue generator and could lead the company to profitability on its own, EXAS has shown a disciplined approach to investing in basic research. It is this ongoing pursuit that makes EXAS interesting as a potential growth stock.

Leaderboard

Find the members with the highest scoring picks in EXAS.

Score Leader

proisback

proisback (85.17) Score: +3,761.97

The Score Leader is the player with the highest score across all their picks in EXAS.

Top
Pick
Member Name Member
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
Index
Gain
Score Commentary
proisback 85.17 9/24/2009 Outperform 3M $2.88 +3,937.50% +175.53% +3,761.97 1 Comment
theonlypro4U < 20 9/23/2009 Outperform 3M $2.89 +3,923.53% +172.53% +3,751.00 1 Comment
chas1232123 < 20 9/23/2009 Outperform 3Y $2.91 +3,896.01% +173.91% +3,722.11 1 Comment
coolyo514 89.23 12/17/2009 Outperform 5Y $2.94 +3,857.66% +165.28% +3,692.38 0 Comment
DUTCHMAN67 65.29 12/17/2009 2/16/2012 Outperform 5Y $2.96 +3,829.71% +165.81% +3,663.89 0 Comment
JavaChipFool 80.01 12/22/2009 Outperform 5Y $2.97 +3,815.02% +162.20% +3,652.82 1 Comment
This player feels very strongly about this pick and has marked it a Top Pick. Top Picks do not affect a player’s score. pantastic 77.61 12/17/2009 Outperform 5Y $2.98 +3,802.14% +165.64% +3,636.50 0 Comment
NickJ100 78.00 12/17/2009 9/24/2014 Outperform 1Y $3.01 +3,763.12% +165.09% +3,598.03 0 Comment
fiberoptical 69.53 12/18/2009 Outperform 3M $3.06 +3,700.00% +166.05% +3,533.95 0 Comment
rdswilson 84.23 12/18/2009 Outperform 5Y $3.06 +3,700.00% +166.05% +3,533.95 0 Comment

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

Player Name Player
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
S&P
Gain
Score End Date Commentary
TrackJimCramer 86.25 5/3/2017 Outperform 3W $31.31 +271.38% +22.94% +248.44 0 Comment
trackcraighallum 51.24 6/16/2016 Outperform NS $9.92 +1,072.18% +41.82% +1,030.35 0 Comment
TrackJimCramer 86.25 7/22/2015 Underperform 3W $25.29 +23.80% +12.87% -10.94 5/3/2017 @ $31.31 0 Comment
TrackGoldmanSach 78.87 6/4/2014 Outperform NS $14.20 +567.82% +50.39% +517.43 4/12/2019 @ $94.83 0 Comment
TrackRothCapital 70.38 12/20/2012 Outperform NS $10.43 +1,014.86% +103.07% +911.79 0 Comment
TrackUltraLong < 20 2/6/2012 Underperform NS $9.57 +1,115.05% +118.23% -996.82 1 Comment
TrackCanaccord 68.02 1/6/2012 Outperform NS $8.41 +1,282.64% +128.70% +1,153.94 0 Comment
TrackJMP 82.82 1/5/2012 Outperform NS $8.12 +1,332.02% +131.33% +1,200.69 0 Comment
TrackRodmanRen < 20 8/15/2011 Outperform NS $6.74 +1,625.22% +145.99% +1,479.24 0 Comment
TrackWedbush 88.31 6/28/2011 Outperform NS $8.03 +1,348.07% +128.25% +1,219.82 0 Comment
TrackTheBenchmar 84.83 4/28/2011 Outperform NS $7.45 +1,460.81% +116.49% +1,344.32 0 Comment
TrackAurigaUSA 64.20 3/1/2011 Outperform NS $5.65 +1,958.05% +119.50% +1,838.55 0 Comment
TrackWMBlair 75.71 12/14/2010 Outperform NS $5.72 +1,932.87% +134.51% +1,798.35 0 Comment
TrackJimCramer 86.25 10/13/2010 Outperform 3W $8.39 +201.43% +79.18% +122.25 7/22/2015 @ $25.29 0 Comment
TrackJefferies 78.27 9/9/2010 Outperform NS $5.17 +2,149.13% +162.60% +1,986.53 0 Comment
TrackRWBaird 89.51 3/4/2010 Outperform NS $4.25 +2,636.00% +160.73% +2,475.27 0 Comment
TrackRodmanRen < 20 2/2/2010 Outperform NS $4.25 +80.24% +14.87% +65.37 8/3/2011 @ $7.66 0 Comment

Advertisement